PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Scope & Guideline

Advancing the Frontiers of Neuropsychopharmacology

Introduction

Welcome to your portal for understanding PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0278-5846
PublisherPERGAMON-ELSEVIER SCIENCE LTD
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1982 to 2024
AbbreviationPROG NEURO-PSYCHOPH / Prog. Neuro-Psychopharmacol. Biol. Psychiatry
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND

Aims and Scopes

The journal "Progress in Neuro-Psychopharmacology & Biological Psychiatry" focuses on advancing the understanding of neuropsychopharmacological processes and biological underpinnings of psychiatric disorders. It publishes research that spans across various methodologies and interdisciplinary approaches that integrate neurobiology, psychopharmacology, and psychiatry.
  1. Neurobiological Mechanisms in Psychiatric Disorders:
    The journal emphasizes research that elucidates the neurobiological mechanisms underlying various psychiatric disorders, including depression, schizophrenia, bipolar disorder, and anxiety disorders. This includes studies on neurotransmitter systems, neuroinflammation, and neuroplasticity.
  2. Pharmacological Interventions and Innovations:
    A core focus is on the evaluation and development of pharmacological treatments for mental health disorders, including traditional medications and novel therapeutic approaches such as psychedelics and cannabinoids.
  3. Translational Research:
    The journal promotes translational research that connects basic neuroscience findings with clinical applications, aiming to bridge the gap between laboratory research and practical treatments in psychiatric care.
  4. Psychobiotics and Gut-Brain Axis:
    There is a growing interest in the role of the gut microbiome in mental health, with research exploring how psychobiotics and gut-brain interactions influence psychiatric conditions and treatment outcomes.
  5. Neuroimaging and Biomarkers:
    The use of neuroimaging techniques and biomarkers to understand psychiatric disorders is a significant focus, facilitating the identification of structural and functional brain changes associated with various mental health conditions.
The journal is currently witnessing several trending and emerging themes that reflect the evolving landscape of research in neuropsychopharmacology and biological psychiatry. Here are some notable trends:
  1. Neuroinflammation as a Key Factor:
    There is an increasing body of research focusing on the role of neuroinflammation in psychiatric disorders, highlighting its impact on disease progression and treatment response.
  2. Psychedelic Research:
    Research into the therapeutic potential of psychedelics for various psychiatric conditions is gaining momentum, with studies investigating their mechanisms of action and clinical efficacy.
  3. Precision Medicine and Biomarkers:
    The emphasis on precision medicine is growing, with a focus on identifying biomarkers that can predict treatment responses and personalize interventions for mental health disorders.
  4. Gut-Brain Axis Research:
    Emerging studies on the gut-brain axis are becoming increasingly prevalent, exploring how gut microbiota influence mental health and the implications for treatment strategies involving probiotics.
  5. Machine Learning and AI in Psychiatry:
    The incorporation of machine learning and artificial intelligence in analyzing neuroimaging and clinical data is on the rise, offering new insights into psychiatric disorders and enhancing diagnostic accuracy.

Declining or Waning

While the journal continues to publish a wide range of topics, certain themes appear to be declining in prominence over recent years. Here are some areas that have shown a decrease in focus:
  1. Traditional Psychopharmacology:
    There seems to be a waning emphasis on traditional psychopharmacological studies focusing solely on established medications, as the field shifts towards exploring novel compounds and integrative approaches.
  2. Behavioral Studies without Biological Correlates:
    Research that primarily investigates behavioral aspects of psychiatric disorders without linking them to biological or neurophysiological mechanisms is becoming less frequent, as the journal seeks more integrative studies.
  3. Longitudinal Studies in Non-Clinical Populations:
    There has been a noticeable reduction in the publication of longitudinal studies examining psychiatric symptoms in non-clinical populations, as the focus pivots towards more targeted clinical and translational research.
  4. Single-Causal Pathway Studies:
    Research that explores single-causal pathways for psychiatric disorders is less common now; there is a shift towards understanding complex interactions and multi-factorial models.

Similar Journals

NEUROPSYCHOBIOLOGY

Transforming Understanding: The Intersection of Neuroscience and Psychology
Publisher: KARGERISSN: 0302-282XFrequency: 6 issues/year

NEUROPSYCHOBIOLOGY, published by KARGER, is a leading academic journal that has been at the forefront of exploring the intricate relationships between neuroscience and psychological processes since its inception in 1975. With both an ISSN of 0302-282X and an E-ISSN of 1423-0224, the journal is renowned for its rigorous peer-reviewed articles and significant contributions to the fields of Biological Psychiatry, Neuropsychology, and Physiological Psychology. Its impact is reflected in its esteemed Scopus rankings, standing out in the 92nd and 81st percentiles in their respective categories. With a commitment to advancing understanding in mental health and neurological science, NEUROPSYCHOBIOLOGY is classified in the Q3 and Q1 quartiles, making it a vital resource for researchers, clinicians, and students alike. Based in Switzerland, the journal embraces a holistic approach to psychological research, bridging gaps between theoretical frameworks and practical applications, thus promoting impactful advancements in the understanding of the human mind.
Explore the latest findings and theories with NEUROPSYCHOBIOLOGY, where your work can contribute to the evolving landscape of neuropsychological studies.

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Bridging Disciplines for Comprehensive Mental Health Solutions
Publisher: SPRINGER HEIDELBERGISSN: 0940-1334Frequency: 6 issues/year

European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.

COMPREHENSIVE PSYCHIATRY

Bridging research and practice in contemporary psychiatry.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0010-440XFrequency: 8 issues/year

COMPREHENSIVE PSYCHIATRY is a leading peer-reviewed journal dedicated to advancing the field of psychiatry and mental health, published by W B SAUNDERS CO-ELSEVIER INC. With its Q1 designation in both Clinical Psychology and Psychiatry and Mental Health, this journal ranks impressively, holding the 9th position out of 311 in Clinical Psychology and the 27th position out of 567 in Psychiatry and Mental Health according to Scopus metrics. Since transitioning to Open Access in 2019, COMPREHENSIVE PSYCHIATRY has significantly increased its accessibility, enabling a broader audience of researchers, mental health professionals, and students to engage with cutting-edge research and clinical practices. The journal's scope encompasses a wide array of topics, including but not limited to evidence-based interventions, psychological evaluations, and the latest empirical studies in the field. As we continue to navigate the complexities of mental health in contemporary society, this journal serves as a vital resource for disseminating impactful findings and fostering collaborative discourse among scholars and practitioners globally.

Current Behavioral Neuroscience Reports

Bridging Neuroscience and Behavior for a Healthier Tomorrow
Publisher: SPRINGERNATUREISSN: Frequency: 4 issues/year

Current Behavioral Neuroscience Reports, published by SPRINGERNATURE, stands at the forefront of advancements in the intricate field of behavioral neuroscience. Since its inception in 2014, this journal has steadily garnered attention within academic circles, boasting a commendable ranking among its peers, including a Q3 classification in Behavioral Neuroscience and a Q2 classification in Public Health, Environmental and Occupational Health as of 2023. Although it operates under traditional access models, the journal is committed to disseminating high-quality research that bridges the gap between neuroscience and behavioral studies, appealing to researchers, professionals, and students alike. With a notable E-ISSN of 2196-2979, Current Behavioral Neuroscience Reports facilitates valuable insights that are critical for understanding the underlying mechanisms of behavior and their implications for public health and environmental factors. This journal is essential for those seeking to contribute to a multidisciplinary dialogue that enhances our comprehension of behavioral neuroscience.

PSYCHIATRY RESEARCH

Shaping the future of psychiatry through impactful findings.
Publisher: ELSEVIER IRELAND LTDISSN: 0165-1781Frequency: 12 issues/year

PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

Neuropsychopharmacology Reports

Advancing mental health through innovative research.
Publisher: WILEYISSN: Frequency: 4 issues/year

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

Cognitive Neuropsychiatry

Shaping Perspectives: Pioneering Research in Cognitive Neuropsychiatry
Publisher: ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTDISSN: 1354-6805Frequency: 6 issues/year

Cognitive Neuropsychiatry is a distinguished academic journal published by Routledge Journals, Taylor & Francis Ltd, dedicated to the intersection of cognitive neuroscience and psychiatry. With a strong commitment to advancing knowledge in these rapidly evolving fields, this journal provides a platform for high-quality, peer-reviewed research that explores cognitive processes underlying psychiatric disorders. Aiming to bridge gaps between neuroscience and clinical practice, it serves as an essential resource for researchers, professionals, and students alike. As evidenced by its performance metrics, the journal ranks in the Q2 quartile for Psychiatry and Mental Health, and Q3 for Cognitive Neuroscience, showcasing its relevance and growing impact, particularly among a competitive audience. While it does not currently offer open access options, Cognitive Neuropsychiatry remains a vital outlet for disseminating impactful findings, offering insights that shape contemporary psychiatric understanding and interventions.

PSYCHIATRY AND CLINICAL NEUROSCIENCES

Fostering Understanding of Neurological and Psychiatric Disorders
Publisher: WILEYISSN: 1323-1316Frequency: 12 issues/year

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

NEUROPSYCHOPHARMACOLOGY

Pioneering Research at the Intersection of Psychiatry and Pharmacology
Publisher: SPRINGERNATUREISSN: 0893-133XFrequency: 13 issues/year

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Exploring the intersection of mind and medicine.
Publisher: OXFORD UNIV PRESSISSN: 1461-1457Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.